OTCMKTS:IMUC EOM Pharmaceuticals (IMUC) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free IMUC Stock Alerts $0.15 -0.03 (-16.48%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.15▼$0.2750-Day Range$0.15▼$0.4052-Week Range$0.15▼$0.40Volume21,718 shsAverage Volume3,967 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get EOM Pharmaceuticals alerts: Email Address Ad WealthPressThe ProTrader Dashboard is simple to use! (trade demo inside)Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.Click here to discover this institutional-grade trading tool for yourself. About EOM Pharmaceuticals Stock (OTCMKTS:IMUC)Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Read More IMUC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUC Stock News HeadlinesJanuary 5, 2024 | uk.finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Inc.March 29, 2024 | WealthPress (Ad)The ProTrader Dashboard is simple to use! (trade demo inside)Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.November 7, 2023 | finance.yahoo.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 4, 2023 | markets.businessinsider.comIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 3, 2023 | msn.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 1, 2023 | morningstar.comOramed Pharmaceuticals Inc ORMPOctober 11, 2023 | markets.businessinsider.comAnalyst Ratings for Olema PharmaceuticalsMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. September 6, 2023 | finance.yahoo.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilAugust 17, 2023 | uk.finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 3, 2023 | msn.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MJuly 17, 2023 | benzinga.comAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 3, 2023 | marketwatch.comAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJune 14, 2023 | marketwatch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentMay 16, 2023 | msn.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 10, 2023 | msn.comPharma CEOs to testify in U.S. Senate hearing on insulin pricesMay 10, 2023 | marketwatch.com8-K: Acumen Pharmaceuticals, Inc.May 9, 2023 | msn.comOlema Pharmaceuticals GAAP EPS of -$0.70 misses by $0.04May 9, 2023 | investing.comOliX Pharmaceuticals Inc (226950)March 30, 2023 | msn.comUSFDA gives final nod to Alembic Pharmaceuticals’ Glaucoma drugMarch 27, 2023 | reuters.comU.S. Supreme Court mulls Amgen bid to revive cholesterol drug patentsMarch 13, 2023 | marketwatch.comRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gainsMarch 11, 2023 | finance.yahoo.comEOM Pharmaceuticals Holdings, Inc. (IMUC)February 24, 2023 | seekingalpha.comIonis Pharmaceuticals, Inc. (IONS) Q4 2022 Earnings Call TranscriptDecember 8, 2022 | technews.tmcnet.comAltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological DiseasesNovember 29, 2022 | marketwatch.comAlaunos Therapeutics Shares Drop 24% After Public Offering PricesSee More Headlines Receive IMUC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for EOM Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2018Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUC CUSIPN/A CIK822411 Webwww.imuc.com Phone(201) 351-0605Fax818-224-5287Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.42 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Irach B. Taraporewala B.S. (Age 68)M.S., Ph.D., CEO, President & Director Comp: $265.65kMr. Wayne I. Danson CPA (Age 70)CFO & Treasurer Comp: $150kMr. Eli Goldberger (Age 34)Founder, Chairman & COO Dr. Shalom Z. Hirschman M.D. (Age 88)Co-Founder, Chief Scientific Officer & Medical Director Key CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAffymaxOTCMKTS:AFFYAlseres PharmaceuticalsOTCMKTS:ALSEView All Competitors IMUC Stock Analysis - Frequently Asked Questions How have IMUC shares performed in 2024? EOM Pharmaceuticals' stock was trading at $0.2320 at the beginning of 2024. Since then, IMUC stock has decreased by 34.5% and is now trading at $0.1520. View the best growth stocks for 2024 here. How were EOM Pharmaceuticals' earnings last quarter? EOM Pharmaceuticals Holdings, Inc. (OTCMKTS:IMUC) issued its earnings results on Monday, August, 13th. The company reported ($0.01) EPS for the quarter. How do I buy shares of EOM Pharmaceuticals? Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMUC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsOnly a fool would buy Nvidia today… Porter & CompanyBill Gates is all about this tiny $2 stockTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EOM Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.